Proc Natl Acad Sci USA 76: 43504354
SURMOUNT-1 demonstrated 15%, 19.5%, and 20.9% body weight reduction at 5, 10, and 15 mg respectively over 72 weeks FDA approvals : Mounjaro (T2D, May 2022) and Zepbound (obesity, November 2023) Cardiovascular outcomes : SURPASS-CVOT in progress to evaluate cardiovascular safety and efficacy Global availability : Approved in US, EU, and numerous international markets Side Effects and Safety Comparison# Mazdutide Side Effects# GI effects : Nausea, diarrhea, and vomiting consistent with GLP-1 class
[2] However, the widespread use of these miracle weight loss drugs may present serious health consequences
Most GLP-1 medications are proteins, and like any protein, they are sensitive to heat and light
What safety considerations apply to compounded GLP-1 therapy regardless of provider
You must be a Costco member to join the program